Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The pharmaceuticals market in Oman has been showing steady growth in recent years, driven by a combination of factors such as an aging population, increasing prevalence of chronic diseases, and rising healthcare expenditure.
Customer preferences: Patients in Oman tend to rely heavily on prescription drugs, with a preference for branded medications over generics. This is partly due to a lack of awareness about the quality and efficacy of generic drugs, as well as the perception that branded drugs are of higher quality. However, there is a growing trend towards the use of generic drugs due to their lower cost.
Trends in the market: One of the key trends in the pharmaceuticals market in Oman is the increasing focus on the development of biopharmaceuticals. This is driven by the growing demand for targeted therapies, as well as the need for more effective treatments for chronic diseases such as cancer and diabetes. In addition, there is a growing trend towards the use of digital technologies in healthcare, which is expected to have a significant impact on the pharmaceuticals market in Oman.
Local special circumstances: One of the unique characteristics of the pharmaceuticals market in Oman is the dominance of government-owned pharmacies, which account for a significant share of the market. This is due to the government's efforts to provide affordable healthcare to the population, which has led to the establishment of a large network of public hospitals and clinics.
Underlying macroeconomic factors: The pharmaceuticals market in Oman is expected to continue growing in the coming years, driven by factors such as increasing healthcare expenditure, a growing population, and rising prevalence of chronic diseases. However, there are also challenges facing the market, such as the lack of a robust regulatory framework and the need for greater investment in research and development.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)